[Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].

Leuppi, Jörg D; Schmid-Grendelmeier, Peter; Rothe, Thomas; von Garnier, Christophe; Simon, Hans-Uwe; Schuoler, Claudio; Pendl, Gunther; Solèr, Markus (2019). [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma]. Praxis, 108(7), pp. 1-8. Hogrefe 10.1024/1661-8157/a003250

[img] Text
1661-8157_a003250.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (2MB) | Request a copy

Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma Abstract:For patients with difficult-to-control, severe bronchial asthma, highly effective, targeted treatment options are available in addition to inhaled medication. In the presence of eosinophilia, inhibition of the interleukin-5 (IL-5) axis with specific monoclonal antibodies promises to be an effective alternative to continuous systemic steroid therapy with few side effects. This review summarizes the data on benralizumab, a specific antibody against the IL-5 receptor alpha preventing receptor stimulation by IL-5 and activating a NK-cell mediated cytotoxic reaction with apoptosis of eosinophils. The s.c.-application of benralizumab leads within days to a virtually complete depletion of blood eosinophils with consecutive improvement in lung function and stabilization of asthma. For selected severe asthmatics, this is a promising therapy option.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Pneumology
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology

UniBE Contributor:

von Garnier, Christophe and Simon, Hans-Uwe

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1661-8157

Publisher:

Hogrefe

Language:

German

Submitter:

Heidi Lobsiger

Date Deposited:

06 Aug 2019 13:08

Last Modified:

06 Aug 2019 13:16

Publisher DOI:

10.1024/1661-8157/a003250

PubMed ID:

31136278

Uncontrolled Keywords:

Asthme sévère Benralizumab Biologika IL-5 Schweres Asthma Severe asthma benralizumab biologic eosinophile Granulozyten eosinophils granulocytes éosinophiles produits biologiques

BORIS DOI:

10.7892/boris.131914

URI:

https://boris.unibe.ch/id/eprint/131914

Actions (login required)

Edit item Edit item
Provide Feedback